1-DODECYL-1H-IMIDAZOLE


UNII	Q11NXV80S7
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JMTFLSQHQSFNTE-UHFFFAOYSA-N
Smiles	CCCCCCCCCCCCn1ccnc1
InChI	InChI=1S/C15H28N2/c1-2-3-4-5-6-7-8-9-10-11-13-17-14-12-16-15-17/h12,14-15H,2-11,13H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H28N2
Molecular Weight	236.4
AlogP	4.9
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	11.0
Polar Surface Area	17.82
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	17.0

Assay Description	Organism	Bioactivity
Induction of precocious metamorphosis-inducing activity against fourth-instar larvae of Bombyx mori Shunrei x shogetsu at 40 ug treated topically in presence of 0.01 ug tebufenozide	Bombyx mori	0.0 %
Induction of precocious metamorphosis-inducing activity against fourth-instar larvae of Bombyx mori Shunrei x shogetsu at 40 ug treated topically in presence of 10 ug methoprene	Bombyx mori	0.0 %
Induction of precocious metamorphosis-inducing activity against fourth-instar larvae of Bombyx mori Shunrei x shogetsu at 40 ug treated topically	Bombyx mori	100.0 %
Induction of precocious metamorphosis-inducing activity against fourth-instar larvae of Bombyx mori Shunrei x shogetsu compound treated topically	Bombyx mori	15.0 ug

Cross References

Resources	Reference
ChEMBL	CHEMBL38032
FDA SRS	Q11NXV80S7
PubChem	78002
SureChEMBL	SCHEMBL284539

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).